[1]
Sateia MJ, Doghramji K, Hauri PJ, Morin CM. Evaluation of chronic insomnia. An American Academy of Sleep Medicine review. Sleep. 2000 Mar 15:23(2):243-308
[PubMed PMID: 10737342]
[2]
Rösner S, Englbrecht C, Wehrle R, Hajak G, Soyka M. Eszopiclone for insomnia. The Cochrane database of systematic reviews. 2018 Oct 10:10(10):CD010703. doi: 10.1002/14651858.CD010703.pub2. Epub 2018 Oct 10
[PubMed PMID: 30303519]
Level 1 (high-level) evidence
[3]
Lichstein KL, Durrence HH, Taylor DJ, Bush AJ, Riedel BW. Quantitative criteria for insomnia. Behaviour research and therapy. 2003 Apr:41(4):427-45
[PubMed PMID: 12643966]
[4]
Ancoli-Israel S, Roth T. Characteristics of insomnia in the United States: results of the 1991 National Sleep Foundation Survey. I. Sleep. 1999 May 1:22 Suppl 2():S347-53
[PubMed PMID: 10394606]
Level 3 (low-level) evidence
[5]
Borbély AA, Achermann P. Ultradian dynamics of sleep after a single dose of benzodiazepine hypnotics. European journal of pharmacology. 1991 Mar 19:195(1):11-8
[PubMed PMID: 2065705]
[6]
Bowery NG. GABAB receptor: a site of therapeutic benefit. Current opinion in pharmacology. 2006 Feb:6(1):37-43
[PubMed PMID: 16361115]
Level 3 (low-level) evidence
[7]
Patel B, Mortensen M, Smart TG. Stoichiometry of δ subunit containing GABA(A) receptors. British journal of pharmacology. 2014 Feb:171(4):985-94. doi: 10.1111/bph.12514. Epub
[PubMed PMID: 24206220]
[8]
Maconochie DJ, Zempel JM, Steinbach JH. How quickly can GABAA receptors open? Neuron. 1994 Jan:12(1):61-71
[PubMed PMID: 8292360]
[9]
Sigel E, Buhr A. The benzodiazepine binding site of GABAA receptors. Trends in pharmacological sciences. 1997 Nov:18(11):425-9
[PubMed PMID: 9426470]
[10]
Winsky-Sommerer R. Role of GABAA receptors in the physiology and pharmacology of sleep. The European journal of neuroscience. 2009 May:29(9):1779-94. doi: 10.1111/j.1460-9568.2009.06716.x. Epub 2009 Apr 27
[PubMed PMID: 19473233]
[11]
Ancoli-Israel S, Walsh JK, Mangano RM, Fujimori M. Zaleplon, A Novel Nonbenzodiazepine Hypnotic, Effectively Treats Insomnia in Elderly Patients Without Causing Rebound Effects. Primary care companion to the Journal of clinical psychiatry. 1999 Aug:1(4):114-120
[PubMed PMID: 15014684]
[12]
Terzano MG, Rossi M, Palomba V, Smerieri A, Parrino L. New drugs for insomnia: comparative tolerability of zopiclone, zolpidem and zaleplon. Drug safety. 2003:26(4):261-82
[PubMed PMID: 12608888]
Level 2 (mid-level) evidence
[13]
Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine. 2017 Feb 15:13(2):307-349. doi: 10.5664/jcsm.6470. Epub 2017 Feb 15
[PubMed PMID: 27998379]
Level 1 (high-level) evidence
[14]
Fry J, Scharf M, Mangano R, Fujimori M. Zaleplon improves sleep without producing rebound effects in outpatients with insomnia. Zaleplon Clinical Study Group. International clinical psychopharmacology. 2000 May:15(3):141-52
[PubMed PMID: 10870872]
[15]
Elie R, Rüther E, Farr I, Emilien G, Salinas E. Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic. Zaleplon Clinical Study Group. The Journal of clinical psychiatry. 1999 Aug:60(8):536-44
[PubMed PMID: 10485636]
[16]
Wikner BN, Källén B. Are hypnotic benzodiazepine receptor agonists teratogenic in humans? Journal of clinical psychopharmacology. 2011 Jun:31(3):356-9. doi: 10.1097/JCP.0b013e3182197055. Epub
[PubMed PMID: 21508851]
[17]
Okun ML, Ebert R, Saini B. A review of sleep-promoting medications used in pregnancy. American journal of obstetrics and gynecology. 2015 Apr:212(4):428-41. doi: 10.1016/j.ajog.2014.10.1106. Epub 2014 Oct 31
[PubMed PMID: 25448509]
[18]
Dolder CR, Nelson MH. Hypnosedative-induced complex behaviours : incidence, mechanisms and management. CNS drugs. 2008:22(12):1021-36. doi: 10.2165/0023210-200822120-00005. Epub
[PubMed PMID: 18998740]
[19]
Forrester MB. Comparison of zolpidem and zaleplon exposures in Texas, 1998-2004. Journal of toxicology and environmental health. Part A. 2006 Oct:69(20):1883-92
[PubMed PMID: 16952907]
[20]
Morgan PT, Kehne JH, Sprenger KJ, Malison RT. Retrograde effects of triazolam and zolpidem on sleep-dependent motor learning in humans. Journal of sleep research. 2010 Mar:19(1 Pt 2):157-64. doi: 10.1111/j.1365-2869.2009.00757.x. Epub 2009 Aug 13
[PubMed PMID: 19682231]
[21]
Verster JC, Volkerts ER, Schreuder AH, Eijken EJ, van Heuckelum JH, Veldhuijzen DS, Verbaten MN, Paty I, Darwish M, Danjou P, Patat A. Residual effects of middle-of-the-night administration of zaleplon and zolpidem on driving ability, memory functions, and psychomotor performance. Journal of clinical psychopharmacology. 2002 Dec:22(6):576-83
[PubMed PMID: 12454557]
[22]
Hindmarch I, Patat A, Stanley N, Paty I, Rigney U. Residual effects of zaleplon and zolpidem following middle of the night administration five hours to one hour before awakening. Human psychopharmacology. 2001 Mar:16(2):159-167
[PubMed PMID: 12404586]
[23]
Stone BM, Turner C, Mills SL, Paty I, Patat A, Darwish M, Danjou P. Noise-induced sleep maintenance insomnia: hypnotic and residual effects of zaleplon. British journal of clinical pharmacology. 2002 Feb:53(2):196-202
[PubMed PMID: 11851645]
[24]
Mets MA, de Vries JM, de Senerpont Domis LM, Volkerts ER, Olivier B, Verster JC. Next-day effects of ramelteon (8 mg), zopiclone (7.5 mg), and placebo on highway driving performance, memory functioning, psychomotor performance, and mood in healthy adult subjects. Sleep. 2011 Oct 1:34(10):1327-34. doi: 10.5665/SLEEP.1272. Epub 2011 Oct 1
[PubMed PMID: 21966064]
[25]
Ben-Hamou M, Marshall NS, Grunstein RR, Saini B, Fois RA. Spontaneous adverse event reports associated with zolpidem in Australia 2001-2008. Journal of sleep research. 2011 Dec:20(4):559-68. doi: 10.1111/j.1365-2869.2011.00919.x. Epub 2011 Apr 11
[PubMed PMID: 21481053]
[26]
Gunja N. In the Zzz zone: the effects of Z-drugs on human performance and driving. Journal of medical toxicology : official journal of the American College of Medical Toxicology. 2013 Jun:9(2):163-71. doi: 10.1007/s13181-013-0294-y. Epub
[PubMed PMID: 23456542]
[27]
Glass J, Lanctôt KL, Herrmann N, Sproule BA, Busto UE. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ (Clinical research ed.). 2005 Nov 19:331(7526):1169
[PubMed PMID: 16284208]
Level 1 (high-level) evidence
[28]
Patat A, Paty I, Hindmarch I. Pharmacodynamic profile of Zaleplon, a new non-benzodiazepine hypnotic agent. Human psychopharmacology. 2001 Jul:16(5):369-392
[PubMed PMID: 12404558]
[29]
Troy SM, Lucki I, Unruh MA, Cevallos WH, Leister CA, Martin PT, Furlan PM, Mangano R. Comparison of the effects of zaleplon, zolpidem, and triazolam on memory, learning, and psychomotor performance. Journal of clinical psychopharmacology. 2000 Jun:20(3):328-37
[PubMed PMID: 10831020]
[30]
Dooley M, Plosker GL. Zaleplon: a review of its use in the treatment of insomnia. Drugs. 2000 Aug:60(2):413-45
[PubMed PMID: 10983740]
[31]
Chen LE, Zhao AD, Zhang QJ, Wu F, Ge ZL, Ge H, Zhan H. Investigation of the usefulness of zaleplon at two doses to induce afternoon-sleep under noise interference and its effects on psychomotor performance and vestibular function. Military Medical Research. 2016:3():5. doi: 10.1186/s40779-016-0075-4. Epub 2016 Mar 1
[PubMed PMID: 26937286]
[33]
Gonzalez M, Goracci L, Cruciani G, Poggesi I. Some considerations on the predictions of pharmacokinetic alterations in subjects with liver disease. Expert opinion on drug metabolism & toxicology. 2014 Oct:10(10):1397-408. doi: 10.1517/17425255.2014.952628. Epub
[PubMed PMID: 25219632]
Level 3 (low-level) evidence
[34]
Stallman HM, Kohler M, White J. Medication induced sleepwalking: A systematic review. Sleep medicine reviews. 2018 Feb:37():105-113. doi: 10.1016/j.smrv.2017.01.005. Epub 2017 Jan 29
[PubMed PMID: 28363449]
Level 1 (high-level) evidence